EP0057349A2 - Peptide-antibiotique, composante B, son procédé de préparation et son emploi dans des médicaments - Google Patents

Peptide-antibiotique, composante B, son procédé de préparation et son emploi dans des médicaments Download PDF

Info

Publication number
EP0057349A2
EP0057349A2 EP82100121A EP82100121A EP0057349A2 EP 0057349 A2 EP0057349 A2 EP 0057349A2 EP 82100121 A EP82100121 A EP 82100121A EP 82100121 A EP82100121 A EP 82100121A EP 0057349 A2 EP0057349 A2 EP 0057349A2
Authority
EP
European Patent Office
Prior art keywords
iron
compound
water
antibiotic
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP82100121A
Other languages
German (de)
English (en)
Other versions
EP0057349A3 (en
EP0057349B1 (fr
Inventor
Karl Georg Dr. Metzger
Jörg Dr. Pfitzner
Delf Dr. Schmidt
Horst Dr. Weyland
Günter Dr. Benz
Theo Dr. Schröder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to AT82100121T priority Critical patent/ATE8132T1/de
Publication of EP0057349A2 publication Critical patent/EP0057349A2/fr
Publication of EP0057349A3 publication Critical patent/EP0057349A3/de
Application granted granted Critical
Publication of EP0057349B1 publication Critical patent/EP0057349B1/fr
Expired legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y10S435/897—Streptomyces griseus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/19—Antibiotic

Definitions

  • the present invention relates to the new compound component B, a microbiological process for its production from a Streptomyces strain and its use as a medicament, in particular as an antimicrobial agent in human and veterinary medicine.
  • nutrient media which contain the customary carbon and nitrogen sources and the necessary salts.
  • the following carbon sources can be used: carbohydrates, in particular polysaccharides, such as starch or dextrins, disaccharides, such as maltose or cane sugar, monosaccharides, such as glucose or xylose, sugar alcohols, such as mannitol or glycerol, carboxylic acids, such as citric acid, malic acid, acetic acid or mixtures thereof, and more naturally occurring mixtures, such as malt extracts.
  • carboxylic acids such as citric acid, malic acid, acetic acid or mixtures thereof, and more naturally occurring mixtures, such as malt extracts.
  • FeCl 3 Iron, zinc, copper, molybdenum, cobalt, nickel and manganese. The presence of about 0.01% FeCl 3 proved to be significant. Some of the mineral salts, including FeCl 3 , are contained in the necessary concentrations in the above-mentioned carbon or nitrogen sources or in the water used as constituents.
  • the pure presentation of the product according to the invention is furthermore achieved by simple chromatography of the active substance mixture on a CM cellulose column in the H + form with dist. Water carried out without any additives.
  • the active eluate, collected in fractions, is lyophilized.
  • An ED 100 (complete cure) is infected in vivo on the white mouse when infected with E. coli Neumann found at 3 mg antibiotic / kg body weight; Therapy: once 30 minutes after infection subcutaneously.
  • the new compound Bay i 3265 component B can be used in conventional pharmaceutical compositions.
  • the pharmaceutical preparations contain the active ingredient according to the invention and customary, suitable, non-toxic carriers and auxiliaries.
  • precultures are used to inoculate a second preculture, a laboratory fermenter, which contains 20 l of the nutrient solution mentioned above, and are incubated at 200 revolutions / min, 10 l air / min and 28 ° C. for 2 days.
  • 20 l of this culture are inoculated into a production fermenter which contains 600 l of nutrient solution with the following composition: 0.7% by weight of citric acid, 0.8% of yeast extract, 0.2% of defatted soybean meal, 0.2% of corn steep liquor and 0.05 % Silicone in tap water.
  • the pH of this nutrient solution is adjusted to 6.4 with potassium hydroxide solution before sterilization.
  • the incubation of the production culture takes place over 2-4 days at 26 ° C with a stirring of 50 revolutions / min and aeration of only 90 l air / min.
  • the fermentation is stopped with optimal antibiotic inhibitory activity of the culture.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP82100121A 1981-01-23 1982-01-11 Peptide-antibiotique, composante B, son procédé de préparation et son emploi dans des médicaments Expired EP0057349B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT82100121T ATE8132T1 (de) 1981-01-23 1982-01-11 Neues peptid-antibiotikum komponente b, verfahren zu seiner herstellung sowie seine verwendung in arzneimitteln.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3102137 1981-01-23
DE19813102137 DE3102137A1 (de) 1981-01-23 1981-01-23 Neue antibiotisch wirksame verbindung, komponente b, mikrobiologisches verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Publications (3)

Publication Number Publication Date
EP0057349A2 true EP0057349A2 (fr) 1982-08-11
EP0057349A3 EP0057349A3 (en) 1982-09-01
EP0057349B1 EP0057349B1 (fr) 1984-06-27

Family

ID=6123195

Family Applications (1)

Application Number Title Priority Date Filing Date
EP82100121A Expired EP0057349B1 (fr) 1981-01-23 1982-01-11 Peptide-antibiotique, composante B, son procédé de préparation et son emploi dans des médicaments

Country Status (6)

Country Link
US (2) US4415557A (fr)
EP (1) EP0057349B1 (fr)
JP (1) JPS57143000A (fr)
AT (1) ATE8132T1 (fr)
DE (2) DE3102137A1 (fr)
ES (1) ES8301274A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0069882A1 (fr) * 1981-07-03 1983-01-19 Bayer Ag Composés à activité antibiotique, procédé de leur préparation et leur emploi en tant que médicament
EP0105393A1 (fr) * 1982-10-01 1984-04-18 Bayer Ag Nouveaux dérivés de nucléosides, leurs méthodes de préparation et leur application comme médicament
EP0144750A2 (fr) * 1983-11-17 1985-06-19 Bayer Ag Antibiotiques, leur méthode de préparation et leur application comme médicament et intermédiaires pour leur préparation

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410056B1 (en) * 1984-03-16 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
US6306647B1 (en) 1987-06-16 2001-10-23 Ajinomoto Co., Inc. Process for producing and purifying 2′,3′-dideoxynucleosides, and process for producing 2′,3′-dideoxy-2′,3′-didehydronucleosides
US4835104A (en) * 1987-06-16 1989-05-30 Ajinomoto Co., Inc., Patent & Licensing Department Process for producing and purifying 2',3'-dideoxynucleosides, and process for producing 2',3'-dideoxy-2',3'-didehydronucleosides
US5869679A (en) * 1997-11-10 1999-02-09 Transcend Therapeutics, Inc. Methods for preparing l-2-oxothiazolidine-4-carboxylate and its carboxylic acid
CN113149990B (zh) * 2020-01-23 2024-04-02 嘉圣生物医药(嘉兴)有限公司 铁载体-二氢叶酸还原酶抑制剂偶联物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158608A (en) * 1975-08-20 1979-06-19 Bayer Aktiengesellschaft Fungicidally active antibiotic from Streptomyces tendae Ettlinger
EP0041180A1 (fr) * 1980-05-31 1981-12-09 Bayer Ag Méthode pour concentrer des mélanges de nikkomycine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB639943A (en) * 1947-02-17 1950-07-12 Upjohn Co Improved method of producing bio-synthetic antimicrobial substances

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158608A (en) * 1975-08-20 1979-06-19 Bayer Aktiengesellschaft Fungicidally active antibiotic from Streptomyces tendae Ettlinger
EP0041180A1 (fr) * 1980-05-31 1981-12-09 Bayer Ag Méthode pour concentrer des mélanges de nikkomycine

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0069882A1 (fr) * 1981-07-03 1983-01-19 Bayer Ag Composés à activité antibiotique, procédé de leur préparation et leur emploi en tant que médicament
EP0105393A1 (fr) * 1982-10-01 1984-04-18 Bayer Ag Nouveaux dérivés de nucléosides, leurs méthodes de préparation et leur application comme médicament
EP0144750A2 (fr) * 1983-11-17 1985-06-19 Bayer Ag Antibiotiques, leur méthode de préparation et leur application comme médicament et intermédiaires pour leur préparation
EP0144750A3 (en) * 1983-11-17 1985-11-13 Bayer Ag Antibiotics, method for their preparation, their use as medicines and intermediates for their preparation

Also Published As

Publication number Publication date
EP0057349A3 (en) 1982-09-01
EP0057349B1 (fr) 1984-06-27
ATE8132T1 (de) 1984-07-15
JPS57143000A (en) 1982-09-03
US4546079A (en) 1985-10-08
DE3102137A1 (de) 1982-08-19
DE3260277D1 (en) 1984-08-02
US4415557A (en) 1983-11-15
ES508985A0 (es) 1982-11-16
ES8301274A1 (es) 1982-11-16

Similar Documents

Publication Publication Date Title
DE2855409A1 (de) Neue aminozucker und verfahren zu ihrer gewinnung
EP0366060B1 (fr) Salbostatine inhibiteur de glycosidase, méthode de sa production et son utilisation
DE2532568A1 (de) Aclacinomycine a und b und verfahren zu ihrer herstellung
EP0013766B1 (fr) Antibiotiques, procédé pour leur préparation et leur utilisation comme agents de protection de végétaux
DE2743654C3 (fr)
EP0057349B1 (fr) Peptide-antibiotique, composante B, son procédé de préparation et son emploi dans des médicaments
EP0057812B1 (fr) Peptide-antibiotique, composante A, son procédé de préparation et son emploi dans des médicaments
CH640246A5 (de) Antibiotische anthracyclinglycoside.
DE2715255B2 (de) Anthracyclinglykoside MA 144-M1 und MA 144-M2 und deren Salze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
DE2638766C2 (de) Antibiotika,Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2556043C3 (de) Antibiotikum Bu-2183, Verfahren zu seiner Herstellung und Arzneimittel
EP0069882B1 (fr) Composés à activité antibiotique, procédé de leur préparation et leur emploi en tant que médicament
EP0197360B1 (fr) Utilisation d'éfomycines pour augmenter le rendement chez les animaux, éfomycines et leur préparation
EP0236894B1 (fr) Efomycine G, sa préparation et son utilisation comme promoteur de croissance pour animaux
CH646712A5 (de) Istamycine und deren herstellung.
EP0259751A2 (fr) Annomycine, un antibiotique; procédé microbiologique pour sa fabrication et son utilisation
DE2946793C2 (de) 4-O-Desmethyl-11-desoxy-anthracyclinglycoside, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE2738656C2 (fr)
EP0173948A2 (fr) Pseudo-oligosaccharides inhibitant l'activité de l'alpha-glucosidase, leur méthode de préparation, leur application et leurs préparations pharmaceutiques
DE2510868C3 (de) Nanaomycin A und Verfahren zur Herstellung der Antibiorica Nanaomycin A und Nanaomycin B
DE2039990C2 (de) Neue Antibiotika B-5050 A bis F (Maridomycin I bis VI), Verfahren zu ihrer Herstellung und ihre pharmazeutische Zubereitung
EP0304400A2 (fr) Dérivés de phénanthridine, procédé pour leur préparation et moyen pour suivre le procédé
DE4231289A1 (de) Neuer Naturstoff Cyclamenol und chemische Derivate
DE2326943C3 (de) Xylostatsin Verfahren zu dessen Herstellung und Xylostatsin enthaltende Arzneimittel
DE1767846C3 (de) Verfahren zur Gewinnung des Antibiotikums NK-1003 bestehend aus 4-O-(6-Amino-6-deoxy-ct-D-glucosyl)- deoxystreptamin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

17P Request for examination filed

Effective date: 19820111

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT NL SE

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT NL SE

ITF It: translation for a ep patent filed

Owner name: ING. C. GREGORJ S.P.A.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI NL SE

REF Corresponds to:

Ref document number: 8132

Country of ref document: AT

Date of ref document: 19840715

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3260277

Country of ref document: DE

Date of ref document: 19840802

ET Fr: translation filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19841218

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19850111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19850112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19850131

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
BERE Be: lapsed

Owner name: BAYER A.G.

Effective date: 19850111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19850801

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19850930

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19870131

Ref country code: CH

Effective date: 19870131

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19871001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19881121

EUG Se: european patent has lapsed

Ref document number: 82100121.1

Effective date: 19860129